The R-enantiomer of IACS-8968 is primarily utilized as an inhibitor targeting both indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO). These enzymes play a critical role in the tryptophan-kynurenine pathway, which is often exploited by cancer cells to suppress immune responses. By inhibiting IDO and TDO, this compound enhances the immune system's ability to recognize and attack tumor cells, making it a promising candidate for cancer immunotherapy. Its application is particularly significant in combination therapies, where it synergizes with checkpoint inhibitors or other immunomodulatory agents to improve therapeutic outcomes. Additionally, research is exploring its potential in treating autoimmune diseases and chronic inflammatory conditions by modulating immune tolerance mechanisms.